Kezdőlap・Részvénylista・AbbVie Inc

AbbVie Inc

Nyitva

SzektorEgészségügy

265.68 2.62

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

250.39

Maximum

259.16

Fő mutatók
By Trading Economics
Bevétel	2.9B 3.6B
Értékesítés	2B 17B
P/E Szektor átlag	70.516 57.371
Egy részvényre jutó nyereség	3.65
Osztalékhozam	2.74
Profit margin	21.283
Munkavállalók	57,000
EBITDA	5B 8.7B

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+8.09% upside

Osztalékok
By Acuity
Osztalékhozam Szektor átlag	2.74% 2.23%
Következő eredményjelentés	2026. okt. 30.
Következő osztalékfizetési dátum	2026. nov. 13.
Következő korábbi osztalék dátum	2026. okt. 14.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-12B 442B
Előző nyitás	263.06
Előző zárás	265.68

Hangulat hírek alapján

By Acuity

26%

74%

87 / 340 Rangsor szerint Healthcare

AbbVie Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 18. 23:51 UTC

Abbvie Inc shares are trading higher in after-market hours, reflecting resilience amid elevated bond yields and inflation concerns. The stock remains above its 20-day moving average.

2026. aug. 17. 23:51 UTC

AbbVie Inc shares are trading lower in after-market hours amid weak broader market sentiment influenced by geopolitical tensions and rising crude oil prices.

2026. aug. 14. 19:46 UTC

Social Media

AbbVie Inc has begun a Phase 2 trial for ABBV-295, yet shares are lower amid negative market sentiment from a decline in U.S. retail sales.

2026. aug. 13. 23:21 UTC

Abbvie Inc shares are lower in after-market hours, with no specific news identified for the decline. Initial jobless claims rose unexpectedly today.

2026. aug. 12. 20:06 UTC

News

Macro Event

AbbVie Inc. shares are lower today, continuing a decline since Tuesday's close, despite FDA acceptance of a BOTOX Cosmetic application for jawline contouring.

2026. aug. 11. 20:06 UTC

News

AbbVie shares are higher as BNP Paribas raises the price target to $247. Allergan Aesthetics enhances its Partner Privileges program to boost customer engagement.

2026. aug. 10. 23:06 UTC

AbbVie Inc shares are lower in after-market hours amid mixed market sentiment influenced by geopolitical tensions and President Trump's comments on economic pressure.

2026. aug. 7. 23:01 UTC

AbbVie Inc shares are trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains near its one-month low.

2026. aug. 6. 20:06 UTC

Social Media

AbbVie Inc shares are lower as bearish sentiment grows in biotech and pharma sectors, with discussions highlighting potential resistance and negative momentum patterns.

2026. aug. 5. 19:26 UTC

News

Event

AbbVie shares are higher as Canada's Drug Agency recommends UBRELVY for migraine treatment. The company also raised its 2026 revenue outlook to $67.60 billion.

2026. aug. 4. 23:01 UTC

Event

AbbVie Inc shares are higher in after-market hours following a recommendation for UBRELVY® reimbursement by Canada's Drug Agency, enhancing patient accessibility.

2026. aug. 3. 23:06 UTC

News

Canaccord Genuity raised its price target for AbbVie to $290, contributing to a modest increase in shares during after-market hours.

2026. júl. 31. 20:04 UTC

News

Event

AbbVie Inc. lowered its 2026 adjusted earnings guidance, now projecting $13.87 to $14.07 per share, contributing to a decline in its stock price today.

2026. júl. 30. 22:41 UTC

Social Media

Event

AbbVie Inc announced JUVÉDERM® Day for August 19, 2026, boosting shares higher in after-market hours amid strong trading activity.

2026. júl. 29. 23:06 UTC

Event

The European Commission approved RINVOQ® for severe alopecia areata, contributing to higher after-market hours trading for Abbvie Inc. Shares remain above their 20-day moving average.

2026. júl. 28. 23:06 UTC

AbbVie Inc. shares traded higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

2026. júl. 27. 19:46 UTC

Social Media

AbbVie Inc. shares are trading lower amid a broader market decline, influenced by falling crude oil prices despite recent social media discussions on its 52-week high.

2026. júl. 24. 23:51 UTC

Social Media

Abbvie shares are trading lower in after-market hours despite a presentation on ABBV-CLS-484, a novel cancer immunotherapy inhibitor.

2026. júl. 23. 10:16 UTC

AbbVie Inc shares are trading lower in pre-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

2026. júl. 22. 23:06 UTC

AbbVie Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement, amid broader market volatility.

2026. júl. 21. 19:06 UTC

Abbvie Inc. is higher today, supported by broader market gains and optimism in the semiconductor sector after TSMC's potential price increases by 2027.

2026. júl. 20. 23:01 UTC

AbbVie Inc. shares are lower in after-hours trading following a decline from earlier gains, remaining above the 20-day moving average.

Társak összehasonlítása

Árváltozás

AbbVie Inc Előrejelzés

Célár

By TipRanks

8.09% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 279.86 USD 8.09%

Magas 300 USD

Alacsony 225 USD

23 Wall Street elemző 12 hónapos célárain alapulva a(z)AbbVie Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

23 ratings

Vétel

Tartás

Eladás

23 Wall Street elemző célárain alapulva a(z)AbbVie Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

87 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.